CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Intravenous Treprostinildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03055221
NCT03055221Phase 4Completed
CompareCT.gov

TRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)

United Therapeutics·interventional·Posted Feb 16, 2017·Updated Jan 5, 2024

In Brief

A Phase 4 clinical trial evaluating Intravenous Treprostinil for Pulmonary Arterial Hypertension. Completed, enrolled 20 participants.

Detailed Summary

This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study RIV-PH-402 were eligible to enroll.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 16, 2017
Enrollment StartJun 10, 2005
Primary CompletionFeb 25, 2014
TodayJul 2, 2026
Enrollment to primary: 8.7 yearsPosted 9.4 years ago

Interventions

Intravenous Treprostinildrug

Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.